{"id":820339,"date":"2025-03-03T06:51:04","date_gmt":"2025-03-03T11:51:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/"},"modified":"2025-03-03T06:51:04","modified_gmt":"2025-03-03T11:51:04","slug":"pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/","title":{"rendered":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025"},"content":{"rendered":"
\n

ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris<\/a>\u00a0(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:<\/p>\n\n\n\n\n\n
\n Format:<\/strong>\n <\/td>\nFireside Chat<\/td>\n<\/tr>\n
\n Representative:\u00a0<\/strong>\n <\/td>\nBerndt Modig, CEO of Pharvaris<\/td>\n<\/tr>\n
\n Date & Time:<\/strong>\u00a0<\/td>\nMonday, March 10, 9:20 a.m. ET<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

A live audio webcast will also be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>. The audio replay will be available on Pharvaris\u2019 website for 30 days following the presentation.<\/p>\n

\n About Pharvaris<\/strong>
\n
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit\u00a0https:\/\/pharvaris.com\/<\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Contact\r\nMaggie Beller\r\nExecutive Director, Head of Corporate and Investor Communications\r\nmaggie.beller@pharvaris.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris\u00a0(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows: Format: Fireside Chat Representative:\u00a0 Berndt Modig, CEO of Pharvaris Date & Time:\u00a0 Monday, March 10, 9:20 a.m. ET \u00a0 \u00a0 A live audio webcast will also be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. The audio … <\/p>\n
Continue reading “Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris\u00a0(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows: Format: Fireside Chat Representative:\u00a0 Berndt Modig, CEO of Pharvaris Date & Time:\u00a0 Monday, March 10, 9:20 a.m. ET \u00a0 \u00a0 A live audio webcast will also be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. The audio … Continue reading "Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-03T11:51:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025\",\"datePublished\":\"2025-03-03T11:51:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/\"},\"wordCount\":241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/\",\"name\":\"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=\",\"datePublished\":\"2025-03-03T11:51:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk","og_description":"ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) — Pharvaris\u00a0(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows: Format: Fireside Chat Representative:\u00a0 Berndt Modig, CEO of Pharvaris Date & Time:\u00a0 Monday, March 10, 9:20 a.m. ET \u00a0 \u00a0 A live audio webcast will also be available on the Investors section of the Pharvaris website at: https:\/\/ir.pharvaris.com\/news-events\/events-presentations. The audio … Continue reading \"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-03T11:51:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025","datePublished":"2025-03-03T11:51:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/"},"wordCount":241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/","name":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=","datePublished":"2025-03-03T11:51:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NzcwNyM2Nzg3MjA3IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-participate-in-the-leerink-partners-global-healthcare-conference-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}